Adverse effects with long-term cyclosporin for severe psoriasis
Authors:
- 1 March 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 27 (2) , 111-114
Abstract
Summary The use of cyclosporin A (CSA) for the treatment of severe psoriasis is well established. However its use is limited by its adverse effects, especially nephrotoxicity. We reviewed 28 patients...Keywords
This publication has 21 references indexed in Scilit:
- Renal function after 10 years' treatment with cyclosporin for psoriasisBritish Journal of Dermatology, 1998
- Treatment of psoriasis with intermittent short course cyclosporin (Neoral®). A multicentre studyBritish Journal of Dermatology, 1997
- Early clinical development of tazaroteneBritish Journal of Dermatology, 1996
- Long-term use of cyclosporine in dermatologyArchives of Dermatology, 1996
- Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasisBritish Journal of Dermatology, 1993
- Four years of experience with cyclosporin A for psoriasisBritish Journal of Dermatology, 1990
- Long-term cyclosporin for psoriasisBritish Journal of Dermatology, 1989
- Low-dose cyclosporin A in severe psoriasis. A double-blind studyBritish Journal of Dermatology, 1988
- Short-term use of cyclosporin A in severe psoriasisBritish Journal of Dermatology, 1986
- Small-Cell Lung CancerNew England Journal of Medicine, 1979